While the current primary role for BRAF inhibitor and MEK inhibitor is in the treatment of melanoma,15,22, 23, 24 these agents have also been used in the treatment of other cancers including non-small cell lung cancer25 and colorectal cancer.26 The gene discussed is BRAF; the disease is melanoma.